Clinical Trial Update: BR1010 in Patients With Essential Hypertension Patients Who do Not Adequately Respond to Fimasartan/Amlodipine Combination [Phase 3]

View source ↗

Summary

Phase 3 trial update for BR1010 in essential hypertension patients not adequately responding to fimasartan/amlodipine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Hypertension

Drugs mentioned

• BR1010

Snippet

Sponsor: Boryung Pharmaceutical Co., Ltd | Conditions: Essential Hypertension | Phase 3 | Status: COMPLETED